Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491761 |
IN |
37 | 2 |
Disease progression, |
||||
ADO-TRASTUZUMAB EMTANSINE, |
||||
| 2 | 25491844 |
PK |
41 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, |
||||
| 3 | 25492325 |
US |
68 | 1 |
Metastases to peritoneum, Disease progression, Gene mutation, HLA marker study positive, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 4 | 25492530 |
FR |
77 | |
Disease progression, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 5 | 25493521 |
US |
1 | |
Metastases to central nervous system, Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 6 | 25493750 |
JP |
7 | 1 |
Disease progression, Nausea, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 7 | 25494348 |
US |
2 | |
Disease progression, |
||||
AFLIBERCEPT, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DORZOLAMIDE, LATANOPROST, |
||||
| 8 | 25494440 |
US |
1 | |
Disease progression, Schizophrenia, Hallucination, |
||||
CARBAMAZEPINE, OLANZAPINE, BUPROPION, GUANFACINE, GUANFACINE HYDROCHLORIDE, GAUNFACINE, HALOPERIDOL, HALOPERIDOL LACTATE, LORAZEPAM, |
||||
| 9 | 25494458 |
PK |
27 | 1 |
Weight increased, Disease progression, |
||||
BEVACIZUMAB, |
||||
| 10 | 25494669 |
IT |
||
Leukaemia recurrent, Disease progression, Acute graft versus host disease in skin, Off label use, |
||||
FLUDARABINE PHOSPHATE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, CYCLOSPORINE, MELPHALAN, MELPHALAN HYDROCHLORIDE, BUSULFAN, CYTARABINE, METHOTREXATE, METHOTREXATE SODIUM, ARSENIC TRIOXIDE, THIOTEPA, TRETINOIN, TRETINOIN, TRETINOIN, |
||||
| 11 | 25494670 |
CH |
||
Disease progression, |
||||
POLATUZUMAB VEDOTIN, RITUXIMAB, |
||||
| 12 | 25495977 |
RU |
||
Death, Dizziness, Nausea, Disease progression, Dyspnoea, Haemoptysis, Decreased appetite, Dizziness, Nausea, Vomiting, Speech disorder, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 13 | 25496021 |
US |
||
Loss of control of legs, Therapeutic response shortened, Fatigue, Disease progression, Headache, Nausea, Fall, Therapy cessation, |
||||
VUTRISIRAN, |
||||
| 14 | 25490075 |
PL |
66 | 1 |
Epstein-Barr virus infection reactivation, Post transplant lymphoproliferative disorder, Diffuse large B-cell lymphoma, Gastrointestinal perforation, Peritonitis, Disease progression, Abdominal pain, Nausea, Vomiting, Drug ineffective, |
||||
CYCLOSPORINE, CYCLOSPORINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, PREDNISONE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 15 | 25486830 |
JP |
7 | 1 |
Tubulointerstitial nephritis, Disease progression, |
||||
ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 16 | 25487267 |
FR |
44 | 2 |
Therapeutic response decreased, Disease progression, |
||||
PREDNISONE, |
||||
| 17 | 25487270 |
US |
2 | |
Pain in extremity, Disease progression, |
||||
RIPRETINIB, RIPRETINIB, RIPRETINIB, |
||||
| 18 | 25487678 |
JP |
54 | 2 |
Disease recurrence, Disease progression, |
||||
TEMOZOLOMIDE, BEVACIZUMAB, |
||||
| 19 | 25487679 |
PK |
62 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 20 | 25487797 |
PK |
27 | 2 |
Disease progression, |
||||
BEVACIZUMAB, |
||||
| 21 | 25487897 |
SG |
64 | 2 |
Disease progression, Drug ineffective, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 22 | 25488222 |
VN |
2 | |
Disease progression, Hepatic neoplasm, |
||||
| 23 | 25488293 |
JP |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 24 | 25488389 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 25 | 25488393 |
HR |
1 | |
Pneumonia, Disease progression, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 26 | 25488400 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 27 | 25488553 |
US |
68 | 1 |
Disease progression, Faeces discoloured, Metabolic encephalopathy, Acute hepatic failure, Acute kidney injury, Coagulopathy, Endotracheal intubation, Hypotension, Anaemia, Hepatic steatosis, Bladder mass, Haematoma, Cyst, Shock, Overdose, Toxicity to various agents, Acute hepatic failure, Autoimmune hepatitis, Haematemesis, Penile haemorrhage, Upper gastrointestinal haemorrhage, Ascites, Abdominal hernia, Generalised oedema, Pulse absent, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 28 | 25488561 |
KZ |
||
Disease progression, Death, |
||||
ATEZOLIZUMAB, |
||||
| 29 | 25488655 |
GB |
25 | 2 |
Appendicitis, Metastases to abdominal cavity, Disease progression, Pancreatitis, |
||||
CABOZANTINIB, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, LEVOTHYROXINE, OXYCODONE, |
||||
| 30 | 25488729 |
CA |
||
Condition aggravated, Disease progression, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, PREDNISONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, HYDROXYCHLOROQUINE, METHOTREXATE SODIUM, NIFEDIPINE, MESALAMINE, |
||||
| 31 | 25488808 |
CN |
64 | 1 |
Deep vein thrombosis, Cytomegalovirus viraemia, Diarrhoea, Pneumonia, Hypoalbuminaemia, Gastrointestinal haemorrhage, Lymphoproliferative disorder, Protein-losing gastroenteropathy, Disease recurrence, Disease progression, Drug dependence, |
||||
CYCLOSPORINE, CYCLOSPORINE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, |
||||
| 32 | 25489162 |
DE |
1 | |
Disease progression, |
||||
BENDAMUSTINE HCL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, FLUDARABINE PHOSPHATE, LENALIDOMIDE, DOXORUBICIN, DOXORUBICIN, OXALIPLATIN, PREDNISONE, POLATUZUMAB VEDOTIN, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, TAFASITAMAB-CXIX, TREOSULFAN, |
||||
| 33 | 25489899 |
TR |
2 | |
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 34 | 25490005 |
PL |
2 | |
Disease progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 35 | 25490759 |
JP |
72 | 1 |
Disease recurrence, Disease progression, |
||||
TEMOZOLOMIDE, BEVACIZUMAB, |
||||
| 36 | 25494186 |
58 | 2 | |
Liver disorder, Disease progression, |
||||
| 37 | 25481325 |
CN |
31 | 2 |
Disease progression, Off label use, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, TEMOZOLOMIDE, TEMOZOLOMIDE, BEVACIZUMAB, |
||||
| 38 | 25481388 |
GB |
52 | 1 |
Disease progression, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE, |
||||
| 39 | 25481440 |
US |
2 | |
Disease progression, |
||||
CLONAZEPAM, |
||||
| 40 | 25481449 |
JP |
||
Disease progression, |
||||
DENOSUMAB, |
||||
| 41 | 25482218 |
NZ |
2 | |
Lung disorder, Disease progression, |
||||
DOSTARLIMAB, |
||||
| 42 | 25482455 |
AU |
||
Death, Disease progression, |
||||
PRUCALOPRIDE SUCCINATE, |
||||
| 43 | 25482508 |
JO |
41 | 2 |
Hypoaesthesia, Fatigue, Micturition urgency, Disease progression, |
||||
OCRELIZUMAB, |
||||
| 44 | 25482517 |
HU |
61 | 2 |
Disease progression, Immune system disorder, |
||||
FILGRASTIM, |
||||
| 45 | 25482758 |
CN |
61 | 2 |
Cytokine release syndrome, Disease progression, Therapy partial responder, Neutropenia, Febrile neutropenia, Thrombocytopenia, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CISPLATIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, CARFILZOMIB, CARFILZOMIB, DARATUMUMAB, DARATUMUMAB, FLUDARABINE PHOSPHATE, |
||||
| 46 | 25482788 |
GB |
1 | |
Disease progression, |
||||
| 47 | 25483178 |
US |
54 | 2 |
Diabetic ketoacidosis, Streptococcal bacteraemia, Disease progression, Drug ineffective, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 48 | 25483213 |
AT |
1 | |
Lymphadenopathy, Thrombocytopenia, Anaemia, Disease progression, |
||||
RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, VENETOCLAX, VENETOCLAX, BENDAMUSTINE HCL, FLUDARABINE PHOSPHATE, LENALIDOMIDE, IBRUTINIB, |
||||
| 49 | 25483214 |
EG |
58 | 1 |
Liver function test increased, Disease progression, Speech disorder, |
||||
ATEZOLIZUMAB, |
||||
| 50 | 25483459 |
JO |
27 | 1 |
Hypoaesthesia, Muscular weakness, Disease progression, Fatigue, |
||||
OCRELIZUMAB, METHYLPREDNISOLONE, |
||||
| 51 | 25484024 |
PL |
13 | 2 |
Disease progression, Nephropathy toxic, Haemorrhage urinary tract, Renal impairment, Bladder hypertrophy, Haematuria, Thrombosis, Viral haemorrhagic cystitis, |
||||
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE, PREDNISONE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BASILIXIMAB, BASILIXIMAB, CYCLOSPORINE, CYCLOSPORINE, CYCLOSPORINE, CYCLOSPORINE, ETANERCEPT, FILGRASTIM, FILGRASTIM, FILGRASTIM, FOSCARNET SODIUM, FOSCARNET SODIUM, GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, RUXOLITINIB, RUXOLITINIB, ETANERCEPT, BUDESONIDE, BUSULFAN, BUSULFAN, BUSULFAN, CIDOFOVIR ANHYDROUS, MELPHALAN, MELPHALAN HYDROCHLORIDE, |
||||
| 52 | 25484404 |
US |
9 | 2 |
Chronic graft versus host disease, Chronic graft versus host disease in skin, Chronic graft versus host disease oral, Disease progression, Pseudomonas infection, Gait inability, Infection, Off label use, Off label use, |
||||
SIROLIMUS, SIROLIMUS, RITUXIMAB, RITUXIMAB, RUXOLITINIB, RUXOLITINIB, BELUMOSUDIL, |
||||
| 53 | 25484826 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, |
||||
| 54 | 25484954 |
US |
2 | |
Disease progression, |
||||
DOXORUBICIN, PACLITAXEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 55 | 25484967 |
ES |
39 | 1 |
Drug hypersensitivity, Disease progression, Drug ineffective, Therapeutic product effect incomplete, |
||||
GABAPENTIN, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, CLONAZEPAM, METHADONE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, MORPHINE, MORPHINE, MORPHINE, BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE IN DEXTROSE, BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE IN DEXTROSE, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, |
||||
| 56 | 25484993 |
BH |
28 | 2 |
Disease progression, |
||||
TETRABENAZINE, RISPERIDONE, |
||||
| 57 | 25485007 |
US |
47 | 2 |
Disease progression, Drug intolerance, |
||||
FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, OXALIPLATIN, LEUCOVORIN CALCIUM, |
||||
| 58 | 25485017 |
CA |
18 | 2 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 59 | 25485050 |
CN |
41 | 1 |
Disease progression, |
||||
RIVAROXABAN, PREDNISONE, PREDNISONE, |
||||
| 60 | 25485138 |
ES |
2 | |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, NINTEDANIB, NINTEDANIB, NINTEDANIB, NINTEDANIB, GLATIRAMER ACETATE, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER, |
||||
| 61 | 25485351 |
FR |
2 | |
Disease progression, Pulmonary toxicity, Interstitial lung disease, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 62 | 25485362 |
FR |
2 | |
Disease progression, Drug ineffective, Asthenia, Nausea, Vomiting, Diarrhoea, Abdominal pain, Drug intolerance, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 63 | 25485602 |
PL |
28 | 1 |
Renal impairment, Disease progression, Off label use, Leukopenia, Drug ineffective, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOSPORINE, CHLORAMBUCIL, AZATHIOPRINE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, METHYLPREDNISOLONE, RITUXIMAB, |
||||
| 64 | 25486105 |
CA |
2 | |
Disease progression, |
||||
CAPECITABINE, FAM-TRASTUZUMAB DERUXTECAN-NXKI, PACLITAXEL, PALBOCICLIB, |
||||
| 65 | 25486115 |
JP |
2 | |
Death, Disease progression, Underdose, Off label use, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 66 | 25476085 |
CN |
33 | 1 |
Leukopenia, Seizure, Disease progression, Brain neoplasm, Adenocarcinoma, Lymphangiosis carcinomatosa, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, |
||||
| 67 | 25476417 |
ES |
1 | |
Disease progression, |
||||
AZTREONAM, |
||||
| 68 | 25476448 |
IT |
14 | 2 |
Disease progression, Therapeutic product effect incomplete, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, OXALIPLATIN, |
||||
| 69 | 25477254 |
IT |
66 | 1 |
Drug ineffective, Disease progression, |
||||
CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CEFTRIAXONE, CEFTRIAXONE SODIUM, CEFTRIAXONE, CEFTRIAXONE SODIUM, |
||||
| 70 | 25477280 |
DE |
37 | 2 |
Disease progression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 71 | 25477301 |
IT |
40 | 2 |
Neutropenia, Thrombocytopenia, Disease progression, Disease recurrence, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CAPECITABINE, CARBOPLATIN, |
||||
| 72 | 25477312 |
IT |
58 | 1 |
Disease progression, Neuropathy peripheral, |
||||
BORTEZOMIB FOR INJECTION, BORTEZOMIB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, BORTEZOMIB FOR INJECTION, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, |
||||
| 73 | 25477339 |
DK |
69 | 1 |
Neurological symptom, Cerebral aspergillosis, Disease progression, Pneumocystis jirovecii pneumonia, Aphasia, Confusional state, Apraxia, Drug ineffective, Lung infiltration, Pyrexia, Cough, |
||||
CHLORAMBUCIL, CHLORAMBUCIL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, VORICONAZOLE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, DAPSONE GEL, 5%, DAPSONE, DASPONE, PYRIMETHAMINE, |
||||
| 74 | 25477754 |
PK |
54 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 75 | 25477800 |
MY |
8 | 2 |
Disease progression, Drug ineffective, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, IFOSFAMIDE, IFOSFAMIDE, IFOSFAMIDE, IFOSFAMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 76 | 25477967 |
DE |
56 | 1 |
Disease progression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 77 | 25477974 |
DE |
34 | 1 |
Disease progression, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, |
||||
| 78 | 25478058 |
US |
64 | 1 |
Drug ineffective, Disease progression, Vision blurred, Off label use, |
||||
OXALIPLATIN, PREDNISONE, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, TRASTUZUMAB, |
||||
| 79 | 25478270 |
CN |
||
Death, Chronic myeloid leukaemia recurrent, Acute lymphocytic leukaemia recurrent, Central nervous system leukaemia, Hypertriglyceridaemia, Hyperuricaemia, Arterial occlusive disease, Blood creatine phosphokinase increased, Hepatic enzyme increased, Hyperbilirubinaemia, Drug resistance, Drug intolerance, Treatment failure, Unevaluable event, Pigmentation disorder, Proteinuria, Disease progression, Therapeutic product effect incomplete, Rash, |
||||
BLINATUMOMAB, BLINATUMOMAB, BLINATUMOMAB, |
||||
| 80 | 25478315 |
CH |
2 | |
Disease progression, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, LENALIDOMIDE, METHOTREXATE, METHOTREXATE SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, |
||||
| 81 | 25478621 |
IT |
53 | 2 |
Disease progression, |
||||
LETROZOLE, LETROZOLE TABLETS, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 82 | 25478761 |
RU |
1 | |
Disease progression, |
||||
DABRAFENIB, TRAMETINIB, |
||||
| 83 | 25478998 |
AU |
74 | 1 |
Disease progression, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 84 | 25479097 |
TR |
46 | 2 |
Disease progression, Neutropenia, Infection, Diarrhoea, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 85 | 25480022 |
US |
61 | 2 |
Disease progression, |
||||
LENALIDOMIDE, |
||||
| 86 | 25480117 |
CA |
22 | 1 |
Burkitt^s lymphoma stage IV, Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, METHOTREXATE, METHOTREXATE SODIUM, CYTARABINE, |
||||
| 87 | 25480118 |
CA |
42 | 1 |
Burkitt^s lymphoma stage I, Disease progression, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, ETOPOSIDE, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, RITUXIMAB, |
||||
| 88 | 25480292 |
RO |
56 | 1 |
Pneumonia, Systemic candida, Chronic lymphocytic leukaemia recurrent, Malignant melanoma, Disease progression, Therapy non-responder, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, RITUXIMAB, RITUXIMAB, RITUXIMAB, IBRUTINIB, |
||||
| 89 | 25480310 |
FR |
||
Deafness, Deposit eye, Sensory loss, Gait disturbance, Balance disorder, Disease progression, Peripheral swelling, |
||||
VUTRISIRAN, |
||||
| 90 | 25471333 |
CN |
55 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 91 | 25472202 |
DK |
67 | 1 |
Disease progression, Acute hepatic failure, Coma, Hepatic encephalopathy, Alanine aminotransferase increased, Off label use, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, METHYLPREDNISOLONE, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 92 | 25472388 |
US |
1 | |
Disease progression, Needle fatigue, |
||||
INTERFERON BETA-1A, |
||||
| 93 | 25472496 |
DK |
34 | 2 |
Drug ineffective, Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, |
||||
| 94 | 25472499 |
US |
1 | |
Metastases to pelvis, Bone pain, Disease progression, |
||||
ETOPOSIDE PHOSPHATE, CARBOPLATIN, |
||||
| 95 | 25472831 |
CH |
||
Disease progression, Therapeutic response decreased, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, |
||||
| 96 | 25473216 |
US |
||
Disease progression, |
||||
BEVACIZUMAB-AWWB, BEVACIZUMAB-AWWB, |
||||
| 97 | 25473296 |
IT |
67 | 1 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, |
||||
| 98 | 25473527 |
60 | 2 | |
Gastrointestinal haemorrhage, Shock, Red blood cell transfusion, Small intestine carcinoma, Duodenal stenosis, Systemic candida, Enterococcal infection, Haemodynamic instability, Tumour haemorrhage, Pupil fixed, Brain stem syndrome, Areflexia, Cerebrovascular accident, Brain injury, Brain oedema, Pneumocephalus, Haemorrhage intracranial, Disease progression, |
||||
LENVATINIB, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 99 | 25473612 |
CN |
||
Hemiplegia, Bone pain, Disease progression, Off label use, |
||||
| 100 | 25473758 |
US |
||
Metabolic dysfunction-associated steatohepatitis, Disease progression, Hepatic pain, Abdominal pain upper, Diarrhoea, Rash, Pruritus, |
||||
RESMETIROM, RESMETIROM, DIPHENHYDRAMINE HYDROCHLORIDE, BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29